Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing open-label study of ACT-385781A (epoprostenol) in pulmonary arterial hypertension
jRCT1080222096Phase 4
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoprostenol in Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH), connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and 1 more, sponsored by Actelion Pharmaceuticals Ltd.
02
Drugs
epoprostenol
03
Conditions
Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT1080222096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222096.